Neuroendocrine Tumors and Peptide Receptor Radionuclide Therapy: When Is the Right Time?
Published 2022 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Neuroendocrine Tumors and Peptide Receptor Radionuclide Therapy: When Is the Right Time?
Authors
Keywords
-
Journal
JOURNAL OF CLINICAL ONCOLOGY
Volume -, Issue -, Pages -
Publisher
American Society of Clinical Oncology (ASCO)
Online
2022-06-02
DOI
10.1200/jco.22.00176
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Dosimetry in radionuclide therapy: the clinical role of measuring radiation dose
- (2022) Courtney Lawhn-Heath et al. LANCET ONCOLOGY
- Spartalizumab in metastatic, well/poorly-differentiated neuroendocrine neoplasms
- (2021) James C Yao et al. ENDOCRINE-RELATED CANCER
- Evolution of the Mesenteric Mass in Small Intestinal Neuroendocrine Tumours
- (2021) Anela Blažević et al. Cancers
- Consensus on molecular imaging and theranostics in neuroendocrine neoplasms
- (2021) Valentina Ambrosini et al. EUROPEAN JOURNAL OF CANCER
- Dual Positron Emission Tomography imaging in bronchial neuroendocrine neoplasms (NENs): The NETPET score as a prognostic biomarker
- (2021) David L Chan et al. JOURNAL OF NUCLEAR MEDICINE
- Long-term hematologic toxicity of 177Lu-octreotate-capecitabine-temozolomide therapy of GEPNET
- (2021) Murali Kesavan et al. ENDOCRINE-RELATED CANCER
- Survival predictors of 177Lu-Dotatate peptide receptor radionuclide therapy (PRRT) in patients with progressive well-differentiated neuroendocrine tumors (NETS)
- (2021) Mina M. Swiha et al. JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
- Radioembolization Versus Bland or Chemoembolization for Liver-Dominant Neuroendocrine Tumors: Is it an Either/Or Question?
- (2021) Jonathan R. Strosberg et al. JOURNAL OF NUCLEAR MEDICINE
- Dosimetric quantities of neuroendocrine tumors over treatment cycles with 177Lu-DOTA-TATE
- (2021) Daniel Roth et al. JOURNAL OF NUCLEAR MEDICINE
- Target Heterogeneity in Oncology: The Best Predictor for Differential Response to Radioligand Therapy in Neuroendocrine Tumors and Prostate Cancer
- (2021) Ameya D Puranik et al. Cancers
- Longitudinal Copy-Number Alteration Analysis in Plasma Cell-Free DNA of Neuroendocrine Neoplasms is a Novel Specific Biomarker for Diagnosis, Prognosis, and Follow-up
- (2021) Gitta Boons et al. CLINICAL CANCER RESEARCH
- Efficacy and safety of high-dose lanreotide autogel in patients with progressive pancreatic or midgut neuroendocrine tumours: CLARINET FORTE phase 2 study results
- (2021) Marianne Pavel et al. EUROPEAN JOURNAL OF CANCER
- 177Lu-Dotatate plus long-acting octreotide versus high‑dose long-acting octreotide in patients with midgut neuroendocrine tumours (NETTER-1): final overall survival and long-term safety results from an open-label, randomised, controlled, phase 3 trial
- (2021) Jonathan R Strosberg et al. LANCET ONCOLOGY
- Efficacy and Safety of Pembrolizumab in Previously Treated Advanced Neuroendocrine Tumors: Results From the Phase 2 KEYNOTE-158 Study
- (2020) Jonathan R Strosberg et al. CLINICAL CANCER RESEARCH
- Impact of liver tumour burden, alkaline phosphatase elevation, and target lesion size on treatment outcomes with 177Lu-Dotatate: an analysis of the NETTER-1 study
- (2020) Jonathan Strosberg et al. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
- NANETS/SNMMI Consensus Statement on Patient Selection and Appropriate Use of 177Lu-DOTATATE Peptide Receptor Radionuclide Therapy
- (2020) Thomas A. Hope et al. JOURNAL OF NUCLEAR MEDICINE
- Gastroenteropancreatic neuroendocrine neoplasms: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
- (2020) M. Pavel et al. ANNALS OF ONCOLOGY
- Risk of bowel obstruction in patients with mesenteric/peritoneal disease receiving peptide receptor radionuclide therapy (PRRT)
- (2020) Jonathan R. Strosberg et al. JOURNAL OF NUCLEAR MEDICINE
- Intra-arterial Peptide Receptor Radionuclide Therapy using 90Y DOTATOC for Hepatic Metastases of Neuroendocrine Tumors
- (2020) Courtney Lawhn-Heath et al. JOURNAL OF NUCLEAR MEDICINE
- The North American Neuroendocrine Tumor Society Consensus Guidelines for Surveillance and Medical Management of Pancreatic Neuroendocrine Tumors
- (2020) Thorvardur R. Halfdanarson et al. PANCREAS
- Enhancing the anti-tumour activity of 177Lu-DOTA-octreotate radionuclide therapy in somatostatin receptor-2 expressing tumour models by targeting PARP
- (2020) Carleen Cullinane et al. Scientific Reports
- 18F-FDG-PET is superior to WHO grading as prognostic tool in neuroendocrine neoplasms and useful in guiding peptide receptor radionuclide therapy: a prospective 10-year follow-up study of 166 patients
- (2020) Tina Binderup et al. JOURNAL OF NUCLEAR MEDICINE
- Surufatinib in advanced extrapancreatic neuroendocrine tumours (SANET-ep): a randomised, double-blind, placebo-controlled, phase 3 study
- (2020) Jianming Xu et al. LANCET ONCOLOGY
- Surufatinib in advanced pancreatic neuroendocrine tumours (SANET-p): a randomised, double-blind, placebo-controlled, phase 3 study
- (2020) Jianming Xu et al. LANCET ONCOLOGY
- A novel time-activity information sharing approach using nonlinear mixed models for patient-specific dosimetry with reduced imaging time points: application in SPECT/CT imaging post-177Lu-DOTATATE
- (2020) Theresa Devasia et al. JOURNAL OF NUCLEAR MEDICINE
- Tumor growth rate as a metric of progression, response, and prognosis in pancreatic and intestinal neuroendocrine tumors
- (2019) Clarisse Dromain et al. BMC CANCER
- 111In-pentetreotide scintigraphy vs. 68Ga-DOTATATE PET: Impact on Krenning Scores and Effect of Tumor Burden
- (2019) Thomas A. Hope et al. JOURNAL OF NUCLEAR MEDICINE
- Characteristics and outcomes of therapy-related myeloid neoplasms after peptide receptor radionuclide/chemoradionuclide therapy (PRRT/PRCRT) for metastatic neuroendocrine neoplasia: a single-institution series
- (2019) Isaac Goncalves et al. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
- NANETS/SNMMI Procedure Standard for Somatostatin Receptor–Based Peptide Receptor Radionuclide Therapy with 177Lu-DOTATATE
- (2019) Thomas A. Hope et al. JOURNAL OF NUCLEAR MEDICINE
- Prognostic Significance of Somatostatin Receptor Heterogeneity in Progressive Neuroendocrine Tumor Treated with Lu-177 DOTATOC or Lu-177 DOTATATE
- (2019) Josephine Graf et al. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
- Peritoneal carcinomatosis in gastro-entero-pancreatic neuroendocrine neoplasms: clinical impact and effectiveness of the available therapeutic options
- (2019) ELETTRA MEROLA et al. NEUROENDOCRINOLOGY
- Radioembolization with 90Y Resin Microspheres of Neuroendocrine Liver Metastases After Initial Peptide Receptor Radionuclide Therapy
- (2019) A. J. A. T. Braat et al. CARDIOVASCULAR AND INTERVENTIONAL RADIOLOGY
- Broadening horizons with 225Ac-DOTATATE targeted alpha therapy for gastroenteropancreatic neuroendocrine tumour patients stable or refractory to 177Lu-DOTATATE PRRT: first clinical experience on the efficacy and safety
- (2019) Sanjana Ballal et al. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
- PRRT neuroendocrine tumor response monitored using circulating transcript analysis: the NETest
- (2019) Lisa Bodei et al. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
- PRRT genomic signature in blood for prediction of 177Lu-octreotate efficacy
- (2018) Lisa Bodei et al. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
- Prospective observational study of 177Lu-DOTA-octreotate therapy in 200 patients with advanced metastasized neuroendocrine tumours (NETs): feasibility and impact of a dosimetry-guided study protocol on outcome and toxicity
- (2018) Ulrike Garske-Román et al. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
- Prognostic Utility of Total 68 Ga-DOTATATE-Avid Tumor Volume in Patients With Neuroendocrine Tumors
- (2018) Amit Tirosh et al. GASTROENTEROLOGY
- Health-Related Quality of Life in Patients With Progressive Midgut Neuroendocrine Tumors Treated With 177Lu-Dotatate in the Phase III NETTER-1 Trial
- (2018) Jonathan Strosberg et al. JOURNAL OF CLINICAL ONCOLOGY
- Pre-therapy Somatostatin Receptor-Based Heterogeneity Predicts Overall Survival in Pancreatic Neuroendocrine Tumor Patients Undergoing Peptide Receptor Radionuclide Therapy
- (2018) Rudolf A. Werner et al. MOLECULAR IMAGING AND BIOLOGY
- Follow-Up for Resected Gastroenteropancreatic Neuroendocrine Tumours: A Practice Survey of the Commonwealth Neuroendocrine Tumour Collaboration (CommNETS) and the North American Neuroendocrine Tumor Society (NANETS)
- (2018) David L. Chan et al. NEUROENDOCRINOLOGY
- Salvage peptide receptor radionuclide therapy with [177Lu-DOTA,Tyr3]octreotate in patients with bronchial and gastroenteropancreatic neuroendocrine tumours
- (2018) W. A. van der Zwan et al. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
- A randomized study of temozolomide or temozolomide and capecitabine in patients with advanced pancreatic neuroendocrine tumors: A trial of the ECOG-ACRIN Cancer Research Group (E2211).
- (2018) Pamela L. Kunz et al. JOURNAL OF CLINICAL ONCOLOGY
- Peptide Receptor Radionuclide Therapy in Grade 3 Neuroendocrine Neoplasms: Safety and Survival Analysis in 69 Patients
- (2018) Jingjing Zhang et al. JOURNAL OF NUCLEAR MEDICINE
- A common classification framework for neuroendocrine neoplasms: an International Agency for Research on Cancer (IARC) and World Health Organization (WHO) expert consensus proposal
- (2018) Guido Rindi et al. MODERN PATHOLOGY
- Treatment with Octreotide in Patients with Well-Differentiated Neuroendocrine Tumors of the Ileum: Prognostic Stratification with Ga-68-DOTA-TATE Positron Emission Tomography
- (2018) Walter Koch et al. Molecular Imaging
- Personalized 177Lu-octreotate peptide receptor radionuclide therapy of neuroendocrine tumours: initial results from the P-PRRT trial
- (2018) Michela Del Prete et al. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
- Peptide receptor radionuclide therapy in gastroenteropancreatic NEN G3: a multicenter cohort study
- (2018) Esben Andreas Carlsen et al. ENDOCRINE-RELATED CANCER
- Peptide receptor radionuclide therapy (PRRT) in European Neuroendocrine Tumour Society (ENETS) grade 3 (G3) neuroendocrine neoplasia (NEN) - a single-institution retrospective analysis
- (2017) Sue Ping Thang et al. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
- ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Neoplasms: Systemic Therapy - Chemotherapy
- (2017) Rocio Garcia-Carbonero et al. NEUROENDOCRINOLOGY
- ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Neoplasms: Peptide Receptor Radionuclide Therapy with Radiolabelled Somatostatin Analogues
- (2017) Rodney J. Hicks et al. NEUROENDOCRINOLOGY
- Phase 3 Trial of 177Lu-Dotatate for Midgut Neuroendocrine Tumors
- (2017) Jonathan Strosberg et al. NEW ENGLAND JOURNAL OF MEDICINE
- The North American Neuroendocrine Tumor Society Consensus Guidelines for Surveillance and Medical Management of Midgut Neuroendocrine Tumors
- (2017) Jonathan R. Strosberg et al. PANCREAS
- Dual Somatostatin Receptor/FDG PET/CT Imaging in Metastatic Neuroendocrine Tumours: Proposal for a Novel Grading Scheme with Prognostic Significance
- (2017) David LH Chan et al. Theranostics
- Prospective Study of 68Ga-DOTATATE Positron Emission Tomography/Computed Tomography for Detecting Gastro-Entero-Pancreatic Neuroendocrine Tumors and Unknown Primary Sites
- (2016) Samira M. Sadowski et al. JOURNAL OF CLINICAL ONCOLOGY
- Everolimus for the treatment of advanced, non-functional neuroendocrine tumours of the lung or gastrointestinal tract (RADIANT-4): a randomised, placebo-controlled, phase 3 study
- (2016) James C Yao et al. LANCET
- ENETS Consensus Guidelines Update for the Management of Distant Metastatic Disease of Intestinal, Pancreatic, Bronchial Neuroendocrine Neoplasms (NEN) and NEN of Unknown Primary Site
- (2016) M. Pavel et al. NEUROENDOCRINOLOGY
- Peptide Receptor Radionuclide Therapy–Induced Hepatotoxicity in Patients With Metastatic Neuroendocrine Tumors
- (2015) Brian P. Riff et al. CLINICAL NUCLEAR MEDICINE
- Measurement of circulating transcripts and gene cluster analysis predicts and defines therapeutic efficacy of peptide receptor radionuclide therapy (PRRT) in neuroendocrine tumors
- (2015) L. Bodei et al. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
- Dose Response of Pancreatic Neuroendocrine Tumors Treated with Peptide Receptor Radionuclide Therapy Using 177Lu-DOTATATE
- (2015) E. Ilan et al. JOURNAL OF NUCLEAR MEDICINE
- Prognostic Value of 68Ga-DOTANOC PET/CT SUVmax in Patients with Neuroendocrine Tumors of the Pancreas
- (2015) V. Ambrosini et al. JOURNAL OF NUCLEAR MEDICINE
- Somatostatin Receptor Imaging with68Ga DOTATATE PET/CT: Clinical Utility, Normal Patterns, Pearls, and Pitfalls in Interpretation
- (2015) Michael S. Hofman et al. RADIOGRAPHICS
- Outcome of peptide receptor radionuclide therapy with 177Lu-octreotate in advanced grade 1/2 pancreatic neuroendocrine tumours
- (2014) Samer Ezziddin et al. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
- Long-term tolerability of PRRT in 807 patients with neuroendocrine tumours: the value and limitations of clinical factors
- (2014) Lisa Bodei et al. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
- Lanreotide in Metastatic Enteropancreatic Neuroendocrine Tumors
- (2014) Martyn E. Caplin et al. NEW ENGLAND JOURNAL OF MEDICINE
- Peptide receptor radionuclide therapy of neuroendocrine tumors with 90Y-DOTATOC: Is treatment response predictable by pre-therapeutic uptake of 68Ga-DOTATOC?
- (2013) M.Ö. Öksüz et al. Diagnostic and Interventional Imaging
- Does the Pretherapeutic Tumor SUV in 68Ga DOTATOC PET Predict the Absorbed Dose of 177Lu Octreotate?
- (2012) Samer Ezziddin et al. CLINICAL NUCLEAR MEDICINE
- The law of Bergonié and Tribondeau: A nice formula for a first approximation
- (2012) Guillaume Vogin et al. INTERNATIONAL JOURNAL OF RADIATION BIOLOGY
- 90Y Radioembolization After Radiation Exposure from Peptide Receptor Radionuclide Therapy
- (2012) S. Ezziddin et al. JOURNAL OF NUCLEAR MEDICINE
- The tumour sink effect on the biodistribution of 68Ga-DOTA-octreotate: implications for peptide receptor radionuclide therapy
- (2011) Jean-Mathieu Beauregard et al. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
- Chromogranin A and Neuron-Specific Enolase as Prognostic Markers in Patients with Advanced pNET Treated with Everolimus
- (2011) James C. Yao et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Sunitinib Malate for the Treatment of Pancreatic Neuroendocrine Tumors
- (2011) Eric Raymond et al. NEW ENGLAND JOURNAL OF MEDICINE
- Everolimus for Advanced Pancreatic Neuroendocrine Tumors
- (2011) James C. Yao et al. NEW ENGLAND JOURNAL OF MEDICINE
- Intraindividual Comparison of Selective Arterial versus Venous 68Ga-DOTATOC PET/CT in Patients with Gastroenteropancreatic Neuroendocrine Tumors
- (2010) C. Kratochwil et al. CLINICAL CANCER RESEARCH
- 90Y-Edotreotide for Metastatic Carcinoid Refractory to Octreotide
- (2010) David L. Bushnell et al. JOURNAL OF CLINICAL ONCOLOGY
- Placebo-Controlled, Double-Blind, Prospective, Randomized Study on the Effect of Octreotide LAR in the Control of Tumor Growth in Patients With Metastatic Neuroendocrine Midgut Tumors: A Report From the PROMID Study Group
- (2009) Anja Rinke et al. JOURNAL OF CLINICAL ONCOLOGY
- Functional imaging of neuroendocrine tumors with combined PET/CT using68Ga-DOTATATE (DOTA-DPhe1,Tyr3-octreotate) and18F-FDG
- (2008) Irfan Kayani et al. CANCER
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now